HC Wainwright & Co. Maintains Buy on Insmed, Raises Price Target to $245

Benzinga Newsdesk www.benzinga.com Positive 77.9%

Neg 0% Neu 0% Pos 77.9%

HC Wainwright & Co. analyst Andrew S. Fein maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $230 to $245.